Dr. Sherwin was a world-renowned endocrinologist and diabetes researcher, a leader who oversaw the growth of clinical and translational research at Yale, and a
Exenatide OK d for Type 2 Diabetes in Adolescents medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
email article
Below are a few more research highlights.
SoliMix Trial
When managing type 2 diabetes, the once-daily iGlarLixi (Soliqua) edged out the twice-daily premix insulin analog BIAsp 30, according to the SoliMix trial.
The 26-week, open-label trial included adults with poorly controlled type 2 diabetes, defined as a baseline HbA1c between 7.5% and 10%. All participants were on basal insulin, as well as oral antidiabetic agents.
Approved in 2016, iGlarLixi is a fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and the GLP-1 receptor agonist lixisenatide (Lixi). BIAsp 30 is biphasic insulin aspart 30/70, and is a premixed injectable insulin analogue with 30% soluble, rapid-acting insulin aspart plus 70% intermediate-acting protamine-bound aspart.
Over-Reliance on Diabetes Technology Might Be a Thing
Written by Moira McCarthy on January 19, 2021 Fact checked by Jennifer Chesak
agrobacter/Getty Images
Advanced new technology in diabetes care may very well be the best thing to happen to patients since the discovery of insulin. That’s hard to debate.
But now, about 15 years after the first CGM (continuous glucose monitor) came to market, concerns are emerging about whether some people are becoming
too dependent on modern diabetes tech tools.
That is, while CGM generally improves lives, many users panic if these tools or their backend systems experience a glitch. And many providers are worried that the healthcare system may be falling short on helping them know what to do if a device fails or is not otherwise available.